ALLO · Allogene Therapeutics, Inc.
$1.58
-0.03 (-1.56%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$563.15M
Shares
345.49M
Volume · Oct 1
939.98K
Avg daily vol (3M)
6.23M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.60
Open$1.61
Day$1.58–1.66
52W close$1.05–3.06
Avg vol 30d5.6M
Short int59.6M · 17.3% float · 11.3d
Short vol46%
Last earningsAug 12, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 5 wks
filed Aug 12, 2026
call held Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.64M
Trailing 12 months
Net income (TTM)
−$165.49M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-18.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+50.2%
Year over year · more shares
Price change (1Y)
+27.6%
Trailing year
Short interest
17.3%
Latest settlement · 11.3 days to cover
AI Brief
Q2 FY26 earnings call · Aug 12, 2026
Q2 FY26
TL;DR. Allogene's Q2 2026 was highlighted by FDA RMAT and Fast Track designations for cema-cel in 1L LBCL consolidation, accelerated ALPHA3 site activation to ~100 by year-end (six months ahead of plan), and brisk ALLO-329 enrollment with a Q4 2026 clinical update planned; cash runway extends into 2029, though the company posted a $42.7M net loss.
Bullish
- + FDA granted RMAT and Fast Track designations for cema-cel as 1L consolidation therapy in July 2026 following review of the interim futility analysis.
- + ALPHA3 interim futility analysis showed a 41.6% absolute MRD clearance advantage for cema-cel vs observation with a favorable outpatient safety profile and no treatment-related serious adverse events.
- + ALPHA3 site activation target accelerated by six months; ~100 sites now expected active by year-end 2026 versus prior 80-site goal.
- + ALLO-329 RESOLUTION trial enrollment is brisk across dose escalation and lymphodepletion cohorts, with a clinical and translational update on track for Q4 2026.
- + Cash runway projected into 2029 supported by $423.6M in cash, cash equivalents and investments as of June 30, 2026.
Bearish
- − Company reported a Q2 2026 net loss of $42.7M ($0.13 per share).
- − ALLO-316 TRAVERSE program has faced real safety challenges despite notable 31% confirmed ORR in CD70-high RCC.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
−15%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
27%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−20%
trailing
6-month return
−45%
trailing
YTD return
+17%
this year
Relative strength
−57%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+0% holders QoQ · +32 funds added
Insider flow
Distributing
Net -$63.0K over 90 days · 100% sells
Short interest
Rising
17.25% of float · ▲ +0.8% MoM · 11.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
210 holders — near 3-yr high, broad support
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+34%
Y/Y
Free cash flow
$-149.6M
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 12, 2026
Operating expense
· 2026
$165M
GAAP Operating Expenses
· 2026
GAAP
$225M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
27%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+0% holders QoQ · +32 funds added
Insider flow
Distributing
Net -$63.0K over 90 days · 100% sells
Short interest
Rising
17.25% of float · ▲ +0.8% MoM · 11.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
210 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 27%
Range high $3
vs 200-day avg -20%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALLO
this stock
Allogene Therapeutics, Inc.
|
$563.15M | +16.8% | -100.0% | — | 17.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALLO | -4.2% | -19.6% | -45.0% | -20.0% | +16.8% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -3.5% | -19.7% | -57.2% | -19.4% | +5.0% |